List of news related to Microsoft stock price MSFT:

Title: 5 Stocks To Buy Now For March 2025
URL: https://www.forbes.com/sites/investor-hub/article/best-stocks-buy-now-march-2025/
Time Published: 2025-02-24T21:35:02Z
Full Content:
These five stocks represent compelling investment opportunities for March 2025, offering a mix of ... [+] growth potential, competitive advantages, and strong fundamentals. In today's market environment, finding the right stocks requires careful analysis of company fundamentals and broader economic trends. With inflation showing signs of cooling and the Federal Reserve hinting at potential rate cuts later this year, certain sectors are particularly well-positioned for growth. This article examines five compelling stock picks that offer strong potential for capital appreciation and steady returns. These selections come from diverse sectors, including technology, healthcare and consumer discretionary, providing investors with opportunities for portfolio diversification. Each company demonstrates solid fundamentals, strong market positioning, and compelling growth catalysts, making them attractive investment options for March 2025 and beyond. This selection process focused on companies with strong fundamentals, sustainable competitive advantages and clear growth catalysts. I evaluated each stock using a comprehensive framework that considered financial metrics such as revenue growth, profit margins and return on equity, as well as qualitative factors, including market position, management quality and industry trends. Special attention was paid to companies with proven track records of navigating economic uncertainties while maintaining strong balance sheets. Additionally, I considered current market conditions and sector-specific trends that could impact performance over the next 12-24 months. Each company was assessed for its valuation relative to peers and historical averages, ensuring that our picks offer reasonable entry points for investors despite the market's recent gains. Microsoft continues to dominate the enterprise software market while making significant strides in cloud computing and artificial intelligence. The company's Azure cloud platform has become a cornerstone of its business, consistently gaining market share against competitors. Microsoft's strategic acquisition of Activision Blizzard and its partnership with OpenAI has further strengthened its position in gaming and AI technologies, creating multiple growth vectors for the future. Microsoft's compelling investment case rests on its exceptional market position across multiple high-growth segments and its proven ability to monetize new technologies. The company's AI integration across its product suite, particularly in Microsoft 365 and Azure, has created significant competitive advantages and new revenue streams. With enterprise IT spending expected to remain robust and the continued shift toward cloud computing, Microsoft is well-positioned to maintain its growth trajectory. Furthermore, with nearly one billion dollars in cash and liquid assets (MSFT 10K), Microsoft's strong balance sheet provides ample resources for continued innovation and strategic acquisitions. The company's consistent dividend growth and share buyback program offer additional value to shareholders, making it an attractive option for growth and income investors. UnitedHealth Group is the largest healthcare company by revenue globally, operating through two platforms: UnitedHealthcare (health insurance) and Optum (healthcare services). The company's integrated approach to healthcare delivery and technology-driven solutions has created a powerful competitive moat. Its Optum division continues to drive innovation in healthcare delivery while expanding margins. UnitedHealth's combination of scale, technological innovation and vertical integration makes it uniquely positioned to benefit from healthcare sector growth. The company's investments in artificial intelligence and data analytics are improving operational efficiency and patient outcomes while reducing costs. The aging U.S. population and increasing healthcare spending provide strong secular tailwinds for continued growth. The drop in price after its CEO was assassinated brought the company down to a more attractive level. The company's consistent execution and strong financial performance, evidenced by nearly double-digit consecutive quarters of earnings beats, demonstrate management's ability to navigate complex healthcare regulations while maintaining profitability. UnitedHealth's dividend growth history and reasonable payout ratio suggest room for continued dividend increases. This stock looks even more attractive after its 12% drop on February 21, following the U.S. Department of Justice's announcement of a civil fraud probe into the company’s Medicare billing. I believe this lawsuit does not significantly threaten the company’s long-term prospects. The market may be reacting out of fear, especially with the upcoming trial of Luigi Mangione, the suspected murderer of UNH’s CEO, which could be casting a negative spotlight on the company. I suggest waiting for a slightly more significant pullback and buying at $435 per share. Mastercard's global payment network continues benefiting from the shift toward digital payments and e-commerce. The company's technology processes billions of transactions annually across more than 210 countries and territories. Beyond its core payment processing business, Mastercard has successfully expanded into value-added services, including cybersecurity, data analytics, and consulting, creating additional revenue streams and strengthening its relationships with financial institutions. Mastercard's investment appeal lies in its powerful network effects, high margins and exposure to global digital payment trends. The company's asset-light business model generates significant free cash flow, allowing for continued investment in technology and strategic acquisitions. Its expansion into emerging markets and new payment technologies, including blockchain and real-time payments, positions it well for future growth. Recent partnerships with fintech companies and investments in open banking capabilities demonstrate Mastercard's commitment to innovation and market expansion. With global digital payment volumes expected to grow at a CAGR of 20% through 2027, Mastercard is well-positioned to capture a significant share of this growth. Eli Lilly has emerged as a leader in innovative therapeutics, particularly in diabetes, obesity and Alzheimer's disease treatments. The company's GLP-1 receptor agonists, including Mounjaro and Zepbound, have demonstrated exceptional efficacy in treating type 2 diabetes and obesity, creating a massive market opportunity. Additionally, its Alzheimer's drug donanemab has shown promising results in clinical trials. Eli Lilly's strong position in the rapidly growing weight loss drug market represents a significant growth driver. Market estimates suggest the obesity market could reach $100 billion by 2030, with Eli Lilly positioned to capture a substantial share. The company's robust pipeline, including potential breakthrough treatments for Alzheimer's and cancer, provides multiple pathways for future growth. The company's consistent investment in R&D, strong patent protection for key drugs, and proven ability to bring innovative treatments to market make it an attractive long-term investment. With healthcare spending expected to grow globally, Eli Lilly's focus on chronic diseases and unmet medical needs positions it well for sustained growth. Costco's membership-based warehouse club model demonstrates remarkable resilience and growth potential. The company's focus on providing high-quality products at competitive prices has created strong customer loyalty, evidenced by its industry-leading membership renewal rates of over 90%. Costco's expansion into e-commerce and international markets provides additional growth opportunities while maintaining its core value proposition. Costco's competitive advantages stem from its efficient operations, strong purchasing power, and loyal customer base. The company's membership model provides predictable recurring revenue, while its reputation for quality and value helps it maintain market share even during economic downturns. Recent investments in digital capabilities and supply chain optimization have improved operational efficiency and customer experience. The company's international expansion plans, particularly in China and other Asian markets, offer significant growth potential. With 29 new warehouse openings planned for fiscal 2025 and continued growth in e-commerce sales, Costco is well-positioned to maintain its growth trajectory while returning value to shareholders through regular dividends and special dividend payments. Bottom Line These five stocks represent compelling investment opportunities for March 2025, offering a mix of growth potential, competitive advantages, and strong fundamentals. While Microsoft and Mastercard provide exposure to digital transformation and financial technology trends, UnitedHealth Group and Eli Lilly offer stakes in healthcare innovation and demographic trends. Costco rounds out the selection with its defensive characteristics and steady growth potential. When making investment decisions, investors should always consider their investment goals, risk tolerance, and portfolio diversification.
--------------------------------------------------

Title: These 4 Dow Jones Industrial Stocks Are Now In Down Trends
URL: https://www.forbes.com/sites/johnnavin/2025/02/24/these-4-dow-jones-industrial-stocks-are-now-in-down-trends/
Time Published: 2025-02-24T18:03:44Z
Full Content:
Dow Jones Industrials The weakness displayed on the price charts of these major, large capitalization Dow Jones Industrials is not a good sign for stock markets as a whole. Coming after a strong 2024, it’s an adjustment for Wall Street analysts to see how poorly these big names are performing just two months into the new year. These former leaders are having trouble finding the upside again. By downtrend, I mean that the price of each seems unable to power back up to or above the late 2024 high. That’s the first bit of price chart analysis, but there’s more. These stocks have dropped below the significant moving averages where it’s easy to make out the direction of trend, near-term and longer term. Caterpillar (NYSE: CAT) Caterpillar daily price chart, 2 24 25. The November 204 high is near $415. The January high of near $410 meets selling and goes no higher. You can see how the 50-day moving average (the blue line) began to trend downward by mid-December 2024. It looks as if it may cross below the 200-day moving average next or in a few weeks, a sign of further weakness. That the price is below both of the moving averages is not a bullish look and that it’s dropped below the early January low of just under $350 reinforces that. A test of the September 2024 low near $325 may be next. United Healthcare (NYSE: UNH) UnitedHealth Group daily price chart, 2 24 25. The stock peaked in early November at almost $630. The re-test in early December made it up to just $620, a failure to establish a new high. After the long drop to the mid-December low, UnitedHealth could climb no higher than $555 before the selling began again. The 50-day moving average crossed below the 200-day moving average in late January and remains below it. Last week’s big gap down in price to it to below the December low on huge volume as investors seemed to reach the “just sell it” stage. Microsoft (NASD: MSFT) Microsoft daily price chart, 2 24 25. The big cap name is unable to make it back above the early July 2024 high. The attempt to do so in December 2024 fails. The 50-day moving average has turned downward and appears about to cross below the 200-day moving average, signaling the intensity of the weakness. Note that the price has dropped below the previous support levels of the early November 2024 low and is testing the low from early September 2024. If a more serious bout of selling begins, the August 2024 low near $380 may be tested. Merck (NYSE: MRK) Merck daily price chart, 2 24 25. Although the stock has rallied over the last few days, the price has along way to go to look bullish again. The 50-day moving average crossed below the 200-day moving average in early September 2024 and has remained below it since then. The early February 2025 gap down took Merck below the mid-November low. If this month’s gap is filled, the stock would climb above the 50-day moving average. More analysis and commentary at johnnavin.substack.com.
--------------------------------------------------

Title: Nvidia to report Q4 earnings Wednesday as tariff, export control threats loom
URL: https://finance.yahoo.com/news/nvidia-to-report-q4-earnings-wednesday-as-tariff-export-control-threats-loom-090009145.html
Time Published: 2025-02-24T09:00:09Z
Description: Nvidia will report its Q4 earnings after the bell on Wednesday.
--------------------------------------------------